News: Zoetis Inc (ZTS.N)
30.61USD
2:17pm EDT
$0.45 (+1.49%)
$30.16
$30.01
$30.73
$29.91
406,906
1,699,440
$35.40
$28.97
Mon, Jun 24 2013
Pfizer says shareholders snap up remaining Zoetis shares
- Pfizer Inc on Monday said it would complete the spinoff of its Zoetis Inc animal health business after investors offered to trade their Pfizer shares for the company's remaining majority stake in the unit.
UPDATE 2-Pfizer says shareholders snap up remaining Zoetis shares
June 24 - Pfizer Inc on Monday said it would complete the spinoff of its Zoetis Inc animal health business after investors offered to trade their Pfizer shares for the company's remaining majority stake in the unit.
Pfizer says shareholders snap up remaining Zoetis shares
June 24 - Pfizer Inc said on Monday that enough Pfizer shareholders offered to trade their shares for stock in Pfizer's majority owned Zoetis Inc animal health business to allow Pfizer to complete its spinoff of the unit.
Pfizer to spin off Zoetis stake to shareholders
- Pfizer Inc said on Wednesday it will spin off its majority stake in animal health business Zoetis Inc to shareholders by allowing them to swap Pfizer stock for Zoetis shares at a 7 percent discount.
UPDATE 2-Pfizer to spin off Zoetis stake to shareholders
May 22 - Pfizer Inc said on Wednesday it will spin off its majority stake in animal health business Zoetis Inc to shareholders by allowing them to swap Pfizer stock for Zoetis shares at a 7 percent discount.
BRIEF-Pfizer up in premarket after plans to unwind remaining majority stake in Zoetis
NEW YORK, May 22 - Pfizer Inc : * Up 2.2 percent to $29.40 in premarket after plans to unwind remaining majority stake in Zoetis
Strong pet product sales help Zoetis top estimates
- Zoetis Inc , formerly the animal health subsidiary of U.S. pharmaceuticals giant Pfizer Inc , posted a stronger-than-expected quarterly profit, driven by growth in sales of pet products in the United States.
UPDATE 2-Strong pet product sales help Zoetis top estimates
April 30 - Zoetis Inc, formerly the animal health subsidiary of U.S. pharmaceuticals giant Pfizer Inc , posted a stronger-than-expected quarterly profit, driven by growth in sales of pet products in the United States.
Zoetis profit beats Street on strong pet product sales
- Zoetis Inc , formerly the animal health subsidiary of U.S. pharmaceuticals giant Pfizer Inc , posted a better-than-expected quarterly profit, driven by strong growth in sales of pet products in the United States.
Zoetis profit beats Street on strong pet product sales
April 30 - Zoetis Inc, formerly the animal health subsidiary of U.S. pharmaceuticals giant Pfizer Inc , posted a better-than-expected quarterly profit, driven by strong growth in sales of pet products in the United States.
- Here's What This $30 Billion Pension Fund Has Been Buying
- Analysts' Actions: BWLD MJN ZTS
- Should Investors Buy This Animal Health Company Now?
- Analysts' Actions: APD CNC M ZTS
- Allergan And Other Top Buy-And-Sell Picks By Healthcare Sector-Focused Funds
- 1 Final Thought About The Pfizer-Zoetis Tender Offer
Press Releases
- Zoetis Appoints American Express Executive Vice President and General Counsel, Louise Parent, to its Board of Directors
- Today's Technical View: Zoetis, Covidien, Teva Pharma, and Valeant Pharma
- Collaborations, Facility Expansions, and Regulatory Approvals Open Opportunities for Revenue Growth - Research Report on Johnson & Johnson, Zoetis, CVS Caremark, Omnicare, and Novartis
- Trial Results, New Facilities, Approved Labels, Spinoffs, and M&As Support Long-Term Growth Strategies - Research Report on Pfizer, Johnson & Johnson, Merck, Zoetis, and AstraZeneca
- Zoetis Announces Plans to Expand Operations in Lincoln
- Zoetis to Host Webcast and Conference Call on Second-Quarter 2013 Financial Results
- Pfizer Announces Final Results of Zoetis Exchange Offer
- Nutrition - Pharma Stocks in the News: Embark Holdings, GNC, Vitamin Shoppe, Gilead Sciences, Pfizer
- FDA Reviews, Acquisitions, Dividends, and Drug Study Results Highlight Solid Growth for Major Drug Companies - Research Report on Pfizer, Johnson & Johnson, Zoetis, AbbVie, and Lilly
- Zoetis Becomes Fully Independent With Acceptance of Pfizer Shares Tendered in Exchange Offer

